ACIP approved the following recommendations by majority vote at its February 2019 meeting:
- Japanese encephalitis (JE) vaccine
- JE vaccine is recommended for persons moving to a JE-endemic country to take up residence, longer-term (e.g., ≥1 month) travelers to JE-endemic areas, and frequent travelers to JE-endemic areas. JE vaccine also should be considered for shorter-term (e.g., <1 month) travelers with an increased risk of JE based on planned travel duration, season, location, activities, and accommodations. Vaccination also should be considered for travelers to endemic areas who are uncertain of specific duration of travel, destinations, or activities. JE vaccine is not recommended for travelers with very low risk itineraries, such as shorter-term travel limited to urban areas or travel that occurs outside of a well-defined JE virus transmission season.
- In adults aged 18–65 years, the primary vaccination schedule is two doses administered on days 0 and 7–28.
- For adults and children, a booster dose (i.e., third dose) should be given at ≥1 year after completion of the primary JE-VC series if ongoing exposure or re-exposure to JE virus is expected.
- Anthrax Vaccine
- A booster dose of AVA may be given every 3 years to persons not currently at high-risk of exposure to B. anthracis who have been previously primed with AVA and wish to maintain protection.
These recommendations have been adopted by the CDC Director and will become official once published in MMWR.
1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027
To receive email updates about this page, enter your email address: